 |
市場調查報告書
商品編碼
1920942
Frost Radar：抗體藥物複合體(ADC) 合約開發與生產組織 (CDMO)，2025 年Frost Radar: Antibody-Drug Conjugate Contract Development and Manufacturing Organizations, 2025 |
||||||
一套能夠激勵企業的標竿體系－推動新業務創建與成長通路的創新
這份Frost Radar™分析了抗體藥物複合體(ADC) 合約開發和生產組織 (CDMO) 市場的競爭格局。各公司提供 ADC 所需的生產和開發服務，而 ADC 已成為癌症治療領域最具活力和價值的治療方法之一。這場變革癌症治療的 ADC 革命能否成功，直接取決於本分析中重點介紹的專業 CDMO 的能力。了解這些企業的策略、優勢和劣勢，對於生物製藥產業的所有相關人員至關重要。
為了在充滿挑戰的環境中取得成功，CDMO（合約研發生產機構）必須提供全面的端到端服務，包括單株抗體生產、高效能藥物活性原料藥合成、先進的生物偶聯以及無菌灌裝包裝等能力。這些服務必須由先進的設施提供支持，這需要大量的資本投入，以及對管理這些複雜工藝所需的科學和技術人才的同等深度投資。
Frost & Sullivan公司對產業內的眾多公司進行分析。公司因其領導力或其他獨特特徵而被選中，隨後根據10項成長和創新標準進行基準測試，從而揭示其在Frost Radar™上的位置。本刊物分析每家公司的優勢以及與這些優勢最契合的機遇，以呈現Frost Radar™競爭概況。
目錄
策略要務與成長環境
Frost Radar ™：抗體藥物複合體(ADC) 合約開發與生產組織 (CDMO)，2025 年
Frost Radar (TM): C2A（企業行動）
- Abzena
- Ajinomoto Bio-Pharma Services
- Axplora
- Catalent
- ChemExpress
- Lonza
- MabPlex
- Merck KGaA, Darmstadt, Germany
- Piramal Pharma Solutions
- Porton Pharma Solutions
- Recipharm
- Samsung Biologics
- Sterling Pharma Solutions
- Syngene International
- Thermo Fisher Scientific
- WuXi XDC
最佳實踐和成長機會
- 最佳實踐
- 發展機會
Frost Radar™ 分析
後續步驟：利用Frost Radar™ 賦予關鍵相關人員
- 登上Frost Radar ™ 的意義所在
- Frost Radar ™ 為 CEO 成長團隊賦能
- Frost Radar (TM) 幫助投資者
- Frost Radar ™ 幫助客戶
- Frost Radar ™ 支援板
免責聲明
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC revolution, which is transforming cancer treatment, is directly dependent on the capabilities of the specialized CDMOs profiled in this analysis. Understanding the strategies, strengths, and weaknesses of these players is essential for any stakeholder in the biopharmaceutical industry.
To succeed in this demanding environment, a CDMO must provide a comprehensive, end-to-end service offering. This includes capabilities in monoclonal antibody production, high-potency active pharmaceutical ingredient synthesis, advanced bioconjugation, and sterile fill-finish drug product manufacturing. These services must be supported by state-of-the-art facilities that require massive capital investment and an equally deep investment in the scientific and technical talent needed to manage these complex processes.
Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.
Table of Contents
Strategic Imperative and Growth Environment
Frost Radar™: Antibody-Drug Conjugate Contract Development and Manufacturing Organizations, 2025
Frost Radar™: Companies to Action
- Abzena
- Ajinomoto Bio-Pharma Services
- Axplora
- Catalent
- ChemExpress
- Lonza
- MabPlex
- Merck KGaA, Darmstadt, Germany
- Piramal Pharma Solutions
- Porton Pharma Solutions
- Recipharm
- Samsung Biologics
- Sterling Pharma Solutions
- Syngene International
- Thermo Fisher Scientific
- WuXi XDC
Best Practices & Growth Opportunities
- Best Practices
- Growth Opportunities
Frost Radar™ Analytics
Next Steps: Leveraging the Frost Radar™ to Empower Key Stakeholders
- Significance of Being on the Frost Radar™
- Frost Radar™ Empowers the CEO's Growth Team
- Frost Radar™ Empowers Investors
- Frost Radar™ Empowers Customers
- Frost Radar™ Empowers the Board of Directors
Legal Disclaimer
